What is SMMT's current stock price?

SMMT (Summit Therapeutics Inc.) is currently trading at $16.89 with a market cap of $13.10B.

What sector is Summit Therapeutics Inc. in?

Summit Therapeutics Inc. (SMMT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is SMMT a good stock to buy?

Analysts have a Buy consensus on SMMT with a price target of $19.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

SMMT Summit Therapeutics Inc.

Healthcare

$16.89+0.00%OpenMarket Cap: $13.10B

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

31.13

P/S

0.00

EV/EBITDA

-12.09

DCF Value

$0.25

FCF Yield

-2.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-340.6%

ROA

-214.2%

ROIC

-248.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-189.4M	$—
Q4 null	$0.00	$-219.2M	$—
FY null	$0.00	$-1.08B	$—
Q3 null	$0.00	$-231.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$19.00

Target (Median)

$18.00

Target Range

$16.00 - $23.00

1 Strong Buy11 Buy5 Hold0 Sell2 Strong Sell

HC Wainwright & Co.Neutral

2026-05-22

HC Wainwright & Co.Buy

2026-05-04

Piper SandlerNeutral

2026-05-01

StifelBuy

2026-04-08

JefferiesHold

2026-03-16

Trading Activity

Insider Trades

View All

Anand Bhaskarofficer: Chief Accounting Officer

SellMon Jan 12

Zanganeh Mahkamdirector, 10 percent owner, officer: Co-Chief Executive Officer

SellTue Jan 06

Xia Yudirector

SellTue Jan 06

Ronaghi Mostafadirector

SellTue Jan 06

Huber Jeffdirector

SellTue Jan 06

Related AI Research

8-K EventMay 1, 2026

SMMT files 8-K — Item 2.02 Results of Operations

Summit Therapeutics Inc.

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-1.25

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Peers

RNA